产品
编 号：F741790
分子式：C21H33N3O
分子量：343.51
分子式：C21H33N3O
分子量：343.51
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 2763730-97-6
产品详情
生物活性：
SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 plays a key role in development and immune system.
体内研究：
SLF1081851 (20 mg/kg；ip，给药后 4 小时) 显著抑制循环淋巴细胞和血浆 S1P，并重现 Spns2 缺失小鼠的遗传表型。Animal Model:C57BL/6 mice
Dosage:20 mg/kg
Administration:Intraperitoneal injection; blood was drawn 4 h postdose
Result:Significantly decreased circulating lymphocyte count and plasma S1P concentration.
Animal Model:SpragueDawley mice (4-week-old)
Dosage:10 mg/kg
Administration:Intraperitoneal injection; single dose; measured at 0, 0.5, 1, 2, 4, 6, and 24 h postdose
Result:Reached a maximum concentration of 5 μM in blood at 2 h with drug levels sustained at ≥ 2 μM for at least 24 h, proved a half-life of over 8 h in rats. The appearance of SPNS2-IN-1 in circulation correlated with a maximal decrease in lymphocyte count at 4 h (25% lower compared to time =0).
体外研究：
Sphingosine 1-phosphate (S1P) 是一种多效性信号分子，Spns2 发挥维持淋巴 S1P 的功能。 SLF1081851 (compound 16d) (0-5 μM；18- 20 小时) 在 Hela 细胞中抑制 S1P 释放，IC50 值为 1.93 μM。 SLF1081851 (0-30 μM；20 分钟) 抑制 mSphK1 (重组小鼠 SphK) (10 μM) 和 mSphK2 (5 μM) 呈剂量依赖性，表明选择性至少为 15 倍 (SphK1 IC50≥30 μM；SphK2 IC 50≈30 μM)。
SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 plays a key role in development and immune system.
体内研究：
SLF1081851 (20 mg/kg；ip，给药后 4 小时) 显著抑制循环淋巴细胞和血浆 S1P，并重现 Spns2 缺失小鼠的遗传表型。Animal Model:C57BL/6 mice
Dosage:20 mg/kg
Administration:Intraperitoneal injection; blood was drawn 4 h postdose
Result:Significantly decreased circulating lymphocyte count and plasma S1P concentration.
Animal Model:SpragueDawley mice (4-week-old)
Dosage:10 mg/kg
Administration:Intraperitoneal injection; single dose; measured at 0, 0.5, 1, 2, 4, 6, and 24 h postdose
Result:Reached a maximum concentration of 5 μM in blood at 2 h with drug levels sustained at ≥ 2 μM for at least 24 h, proved a half-life of over 8 h in rats. The appearance of SPNS2-IN-1 in circulation correlated with a maximal decrease in lymphocyte count at 4 h (25% lower compared to time =0).
体外研究：
Sphingosine 1-phosphate (S1P) 是一种多效性信号分子，Spns2 发挥维持淋巴 S1P 的功能。 SLF1081851 (compound 16d) (0-5 μM；18- 20 小时) 在 Hela 细胞中抑制 S1P 释放，IC50 值为 1.93 μM。 SLF1081851 (0-30 μM；20 分钟) 抑制 mSphK1 (重组小鼠 SphK) (10 μM) 和 mSphK2 (5 μM) 呈剂量依赖性，表明选择性至少为 15 倍 (SphK1 IC50≥30 μM；SphK2 IC 50≈30 μM)。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备